Moving Care Forward in Advanced NSCLC

Program Goals

Case Study

Importance of Histology and Genotyping in NSCLC

Many Clinicians are Not Testing for EGFR Mutations in Advanced NSCLC

ACCP Guidelines: NSCLC Staging

EBUS for Mutation Analysis

Sensitizing Mutations in EGFR

EGFR Inhibitor Erlotinib: EURTAC

EGFR Inhibitor Afatanib: LUX-Lung 3 and LUX-Lung 6 Trials

Case Study: Initial Treatment and Progression

Mechanisms of Acquired Resistance in EGFR-mutated NSCLC

Emerging Agents for Resistance Caused by EGFR T790M Mutation

ALK Inhibitor Crizotinib: PROFILE 1014

Mechanisms of Acquired Resistance to ALK-Targeted Therapy

ALK Inhibitor Ceritinib

ALK Inhibitor AP26113 (Brigatinib)

ALK Inhibitor Alectinib

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)